<a href="https://laohu8.com/S/MRSN">Mersana Therapeutics Inc.</a> Receives Nasdaq Notice for Non-Compliance with Market Value Listing Rule
Mersana Therapeutics Inc. announced that it has received a notice from the Nasdaq Stock Market's Listing Qualifications Department, indicating that the company is not in compliance with the Nasdaq Listing Rule 5450(b)(2)$(A)$. This rule requires Mersana to maintain a minimum Market Value of Listed Securities (MVLS) of $50 million. The notice, received on September 5, 2025, serves as a notification of deficiency but does not indicate an imminent delisting of the company's common stock, which continues to trade under the symbol "MRSN" on the Nasdaq Global Select Market. Mersana has until March 4, 2026, to regain compliance by achieving an MVLS of $50 million or more for at least ten consecutive business days. Failure to meet this requirement could result in delisting, although the company would have the opportunity to appeal. Mersana is monitoring the situation and exploring options to regain compliance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mersana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087800), on September 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。